Abstract: The present invention provides a compound having the structure: ##STR1## wherein R.sup.1 is hydrogen, benzyl or a substituted benzyl group;X is hydrogen, a flouro, an amino or a substituted amino group;Y is hydrogen, a methoxy, a methylthio, a benzylthio, a methylethyl, a chloro, an amino or a substituted amino group; andY' is an oxo or a thio group; andZ is hydrogen, a hydroxy, a methoxy, a halogen, an amino or a substituted amino group.The present invention also provides a method of synthesizing a compound having the above-identified structure as well as the intermediate compounds produced according to that method.

Abstract: This invention provides a compound having the structure: ##STR1## wherein R.sup.1, R.sup.2, and R.sup.3 are same or different, and are hydrogen, hydroxyl, or fluorine; Z is O, CH.sub.2 or CF.sub.2 ; R is chlorine, bromine, iodine, carbonitrile, carboxylic ester, or carboxamide; and one of W, X and Y is N or N.sup.+ R', wherein R' is methyl or ethyl, and all others are CH; provided that R.sup.1 is not H when R.sup.2 and R.sup.3 are OH, Z is O, R is carboxamide and W is N or N.sup.+ R'.This invention also provides methods of preparing the compounds and a method of treating a mammal having a NAD-dependent enzyme associated disorder.

Abstract: This invention provides a compound having the structure: ##STR1## wherein each R.sub.1, R.sub.2, R.sub.3, and R.sub.4 is independently fluorine, OH or H; Z is O, CH.sub.2 or CF.sub.2 ; each Y is independently OH or F; X.sub.7 is N or CH, X.sub.8 is NH, S or Se; and W is C or N, wherein when W is C, the dashed line (---) represents a double bond and X.sub.9 is N or CH, and wherein when W is N, the dashed line (---) represents a single bond and X.sub.9 is S or Se, or the dashed line (---) represents a double bond and X.sub.9 is N or CH.This invention also provides a pharmaceutical composition comprising the compounds and methods of treating a mammal having an inosine monophosphate dehydrogenase associated disorder.

Abstract: This invention relates to new derivatized solid supports and compounds having the formula: ##STR1## wherein S may be a solid support; L may be a chemical bond or a suitable inorganic or organic linker; Z may be --SO.sub.2 -- or --S--S--; R may be --OH, an H-phosphonate, an alkane-phosphonate, a phosphotriester, a phosphite triester, a phosphite diester, a phosphorothioate, a phosphorodithioate, a phosphoroamidate, a phosphoroamidite, --OR.sup.1, --SR.sup.1, a nucleotide, N, which may be substituted or modified in its sugar, phosphate or base, or an oligonucleotide of the formula --(N).sub.g --R.sup.2, wherein N is as defined above which may be the same or different; g is an integer from one to two hundred; R.sup.1 is a suitable protecting group; and R.sup.2 may be an H-phosphonate, an alkane-phosphonate, a phosphotriester, a phosphite triester, a phosphite diester, a phosphorothioate, a phosphorodithioate, a phosphoroamidate, a phosphoroamidite, --OH, --OR.sup.1, --SR.sup.1, or --O--P(OCH.sub.2 CH.sub.

Abstract: This invention relates to new derivatized solid supports and compounds having the formula: ##STR1## wherein S may be a solid support; L may be a chemical bond or a suitable inorganic or organic linker; Z may be --SO.sub.2 -- or --S--S--; R may be --OH, an H-phosphonate, an alkanephosphonate, a phosphotriester, a phosphite triester, a phosphite diester, a phosphorothioate, a phosphorodithioate, a phosphoroamidate, a phosphoroamidite, --OR.sup.1 --SR.sup.1, a nucleotide, N, which may be substituted or modified in its sugar, phosphate or base or an oligonucleotide of the formula --(N).sub.g, --R.sup.2, wherein N is as defined above which may be the same or different; g is an integer from one to two hundred; R.sup.1 is a suitable protecting group; and R.sup.2 may be an H-phosphonate, an alkane-phosphonate, a phosphotriester, a phosphite triester, a phosphite diester, a phosphorothioate, a phosphorodithioate, a phosphoroamidate, a phosphoroamidite, --OH, --OR.sup.1, --SR.sup.1, or --O--P(OCH.sub.2 CH.sub.

Abstract: This invention provides a compound having the structure: ##STR1## wherein R.sup.1, R.sup.2, and R.sup.3 are same or different, and are hydrogen, hydroxyl, or fluorine; Z is O, CH.sub.2 or CF.sub.2 ; R is chlorine, bromine, iodine, carbonitrile, carboxylic ester, or carboxamide; and one of W, X and Y is N or N.sup.+ R', wherein R' is methyl or ethyl, and all others are CH; provided that R.sup.1 is not H when R.sup.2 and R.sup.3 are OH, Z is O, R is carboxamide and W is N or N.sup.+ R'.This invention also provides methods of preparing the compounds and a method of treating a mammal having a NAD-dependent enzyme associated disorder.

Abstract: A sound absorbing member having excellent sound insulating and absorbing performances comprises a fiber assembly consisting essentially of short fibers and having a thickness of not less than 5 mm, in which new and/or recycled polyester fibers are used as the short fiber and not less than 30% by weight of the polyester fiber used have a fiber-size of not more than 4 denier.

Abstract: The present invention provides a compound having the structure: ##STR1## wherein R.sup.1 is hydrogen, benzyl or a substituted benzyl group;X is hydrogen, a flouro, an amino or a substituted amino group;Y is hydrogen, a methoxy, a methylthio, a benzylthio, a methylethyl, a chloro, an amino or a substituted amino group; andY' is an oxo or a thio group; andZ is hydrogen, a hydroxy, a methoxy, a halogen, an amino or a substituted amino group.The present invention also provides a method of synthesizing a compound having the above-identified structure as well as the intermediate compounds produced according to that method.

Abstract: The present invention provides compounds having the structure: ##STR1## or having the structure: ##STR2## The present invention also provides a pharmaceutical compostion containing the compounds, methods of synthesizing the compounds, as well as methods of inhibiting growth of tumor cells and of treating a subject having a disease characterized by the proliferation of tumor cells.

Abstract: The present invention provides a compound having the structure: ##STR1## wherein R.sup.1 and R.sup.2 are independently the same or different and are hydrogen, an acetyl group; an acyl group having the formula --CO(CH.sub.2).sub.n COCH.sub.3, wherein n=1-3; --CO(CH.sub.2).sub.n COOM, wherein n=1-4 and M is hydrogen, Na or K; or --(CH.sub.2).sub.n COOR, wherein n=1-4 and R is hydrogen, Na, K or an alkyl group having 1 to 5 carbon atoms; a hydroxyalkyl group having the formula --(CH.sub.2).sub.n CH.sub.2 OH, wherein n=1-4; a halo alkyl group having the formula --(CH.sub.2).sub.n CH.sub.2 X, wherein n=1-4 and X is a chloro, bromo, or iodo group; a metal sulfonate (--SO.sub.3 M) wherein M is Na or K; a metal sulfinate (--SO.sub.2 M) wherein M is Na or K; a alkyl sulfonate (--SO.sub.3 R) wherein R is an alkyl group having 1 to 4 carbon atoms such as methyl, ethyl, n-propyl or i-propyl; an alkylsulfonyl group (--SO.sub.

Abstract: The present invention provides a compound having the structure: ##STR1## The present invention also provides a method for synthesizing a compound having the above-identified structure as well as the intermediate compounds produced according to that method. The present invention further provides a pharmaceutical composition comprising the above compounds. Lastly, the present invention provides a method of inhibiting growth of tumor cells.

Abstract: The present invention relates to a composition for, and a method of, treating a hepatitis viral infection in a subject using 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-ethyluracil [FEAU].

Abstract: The compounds of the subject invention can be represented as follows: ##STR1## wherein each of R.sup.1, R.sup.2, R.sup.3, R.sup.4, are the same or different and are hydrogen (H), or a lower alkyl group of from about 1-4 carbon atoms, or a lower alkoxy group of from about 1-4 carbon atoms.R is a substituted aniline ##STR2## wherein one of R.sup.5, R.sup.6, R.sup.7 is an alkanol having the formula --(CH.sub.2).sub.n OH, n=1-4, or its carbamate ester having the formula --(CH.sub.2).sub.n OCONR'R", n=1-4, and wherein R' and R" the same or different lower alkyl groups of from about 1 to 4 carbon atoms, one of R' and R" may be hydrogen (H), and the remaining groups are hydrogen.Additionally, the subject invention provides methods for synthesizing the above-identified compounds, physiologically acceptable compositions containing these compounds and methods for using these compounds to inhibit the growth of tumor cells.

Abstract: This invention concerns compounds having the structure: ##STR1## wherein each of R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.2', R.sup.3', R.sup.4', and R.sup.5', is independently hydrogen (--H), or a hydroxyl (--OH), methoxy (--OMe), methyl (--Me), carboxaldehyde (--CHO) or phenylformazen (Ph--N.dbd.CH--) group.This invention also provides a novel process of synthesizing the compounds of the subject invention, including intermediate compounds useful in the process.The present invention also provides pharmaceutical compositions comprising a pharmaceutically effective amount of a compound according to the subject invention and a pharmaceutically acceptable carrier. Finally, the invention provides spermicidal methods and methods of killing or of retarding the proliferation of, cancer cells.

Abstract: The present invention concerns compounds of the formula: ##STR1## wherein R.sup.1 is hydrogen, a hydroxy group or a methoxy group;R.sup.2 is hydrogen or a methyl group;R.sup.3 is hydrogen or a methyl group;Y is a secondary amino group (NHalkyl) or a tertiary amino group (N(alkyl).sub.2); andZ is hydrogen or a halogen.The invention further provides a method of inhibiting topoisomerase II using a compound having the structure: ##STR2## wherein R.sup.1 is hydrogen, a hydroxy group or a methoxy group;R.sup.2 is hydrogen or a methyl group;R.sup.3 is hydrogen or a methyl group;Y is a halogen, secondary amino group (NHalkyl) or a tertiary amino group (N(alkyl).sub.2); andZ is hydrogen or a halogen.The invention further concerns pharmaceutical compositions which comprise the above-identified compound or the acid salts thereof, and the use of the compound or compositions for treating a malignancy in a subject.

Abstract: The present invention concerns compounds of the formula: ##STR1## wherein R.sup.1 hydrogen, a hydroxyl group or a methoxy group;R.sup.2 is hydrogen or a methyl group;R.sup.3 is hydrogen or a methyl group;Y is a halogen, a secondary amino group or a tertiary amino group; andZ is hydrogen or a halogen.The invention further concerns pharmaceutical compositions which comprises the above-identified compound or the acid salts thereof, and the use of the compound or compositions for treating a malignancy in a subject.

Abstract: The present invention concerns compounds of the formula: ##STR1## wherein R is a lower alkyl group, an aryl group or an alkylaryl group and X and Y are the same or different, and each is OH, NH.sub.2, or SH. The aryl group or the aryl moiety of the alkylaryl group may be unsubstituted, monosubstituted, disubstituted or trisubstituted. If substituted, each substituent may independently be an alkyl group, an alkyloxy group or a halogen.The present invention also provides methods for synthesizing the compounds described above.

Abstract: 2'-Deoxy-2'-fluoro-.beta.-D-arabinofuranosyl nucleosides of the following structure are disclosed: ##STR1## wherein X and Y are the same or different and are hydrogen, OR.sup.3, SR.sup.3, NR.sup.3 N.sup.4 or NHacyl wherein R.sup.3 and R.sup.4 are the same or different and are hydrogen, lower alkyl of 1 to 7 carbon atoms, aralkyl, or aryl;NHacyl is alkanoyl or aroylamide;R.sup.1 and R.sup.2 are the same or different and are hydrogen, acyl or aroyl.

Abstract: A method for synthesizing monofluoromethyl- and difluoromethyluracil nucleosides from the corresponding thymine nucleosides is developed. These compounds which contain a partially fluorinated methyl group at the C-5 position (a new class of nucleosides) are potential antiviral and/or anticancer agents. The major features of the preparative route involve bromination of suitably protected thymine nucleosides followed by fluoride treatment.

Abstract: 2'-Deoxy-2'-fluoro-.beta.-D-arabinofuranosyl nucleosides of the following structure are disclosed: ##STR1## wherein X and Y are the same or different and are hydrogen, OR.sup.3, SR.sup.3, NR.sup.3 R.sup.4 or NHacyl wherein R.sup.3 and R.sup.4 are the same or different and are hydrogen, lower alkyl of 1 to 7 carbon atoms, aralky, or aryl;NHacyl is alkanoyl or aroylamide;R.sup.1 and R.sup.2 are the same or different and are hydrogen, acyl or aroyl.